Compare NBIX & HLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NBIX | HLI |
|---|---|---|
| Founded | 1992 | 1972 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2B | 10.6B |
| IPO Year | 1996 | 2015 |
| Metric | NBIX | HLI |
|---|---|---|
| Price | $130.52 | $156.36 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 22 | 7 |
| Target Price | $180.91 | ★ $194.29 |
| AVG Volume (30 Days) | ★ 1.1M | 448.6K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 1.54% |
| EPS Growth | ★ 41.95 | 41.61 |
| EPS | 4.67 | ★ 4.74 |
| Revenue | $161,626,000.00 | ★ $2,389,416,000.00 |
| Revenue This Year | $24.73 | $13.77 |
| Revenue Next Year | $13.14 | $12.10 |
| P/E Ratio | ★ $27.99 | $32.96 |
| Revenue Growth | ★ 977.51 | 24.81 |
| 52 Week Low | $107.96 | $134.41 |
| 52 Week High | $160.18 | $211.78 |
| Indicator | NBIX | HLI |
|---|---|---|
| Relative Strength Index (RSI) | 51.13 | 51.80 |
| Support Level | $124.62 | $135.21 |
| Resistance Level | $135.88 | $164.25 |
| Average True Range (ATR) | 3.58 | 3.43 |
| MACD | -0.12 | -0.06 |
| Stochastic Oscillator | 59.98 | 36.29 |
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
Houlihan Lokey Inc is an investment bank with expertise in mergers and acquisitions, capital markets, financial restructuring, valuation, and strategic consulting. The firm serves corporations, institutions, and governments world-wide with offices in the United States, Europe, and the Asia-Pacific region. The company operates in three segments. In the Corporate Finance business segment, it provides M&A and capital markets advisory services. Through the Financial Restructuring business segment, the company advises on some of the complex restructurings around the world. The Financial and Valuation Advisory Services business segment provides valuation and financial opinion, and financial and strategic consulting practices in the United States.